Background:The aim of the present study is to evaluate the impact of metastases-directed stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) patients: oligorecurrent PC and oligoprogressive castration-resistant PC (oligo-CRPC).Methods:Inclusion criteria of the present multicentre retrospective analysis were: (1) oligorecurrent PC, defined as the presence of 1-3 lesions (bone or nodes) detected with choline positron emission tomography or CT plus bone scan following biochemical recurrence; (2) oligo-CRPC, defined as metastases (bone or nodes) detected after a prostatic-specific antigen rise during androgen deprivation therapy (ADT). Primary end points were: distant progression-free survival (DPFS) and ADT-free survival in oligorecurrent PC patients; DPFS and second-line systemic treatment-free survival in oligo-CRPC patients.Results:About 100 patients with oligorecurrent PC (139 lesions) and 41 with oligo-CRPC (70 lesions), treated between March 2010 and April 2016, were analysed. After a median follow-up of 20.4 months, in the oligorecurrent group 1-and 2-year DPFS were 64.4 and 43%. The rate of LC was 92.8% at 2 years. At a median follow-up of 23.4 months, in the oligo-CRPC group 1-and 2-year DPFS were 43.2 and 21.6%. Limitations include the retrospective design.Conclusions:Stereotactic body radiotherapy seems to be a useful treatment both for oligorecurrent and oligo-CRPC.

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: New evidence from a multicentric study / Triggiani, Luca; Alongi, Filippo; Buglione, Michela; Detti, Beatrice; Santoni, Riccardo; Bruni, Alessio; Maranzano, Ernesto; Lohr, Frank; D'Angelillo, Rolando; Magli, Alessandro; Bonetta, Alberto; Mazzola, Rosario; Pasinetti, Nadia; Francolini, Giulio; Ingrosso, Gianluca; Trippa, Fabio; Fersino, Sergio; Borghetti, Paolo; Ghirardelli, Paolo; Magrini, Stefano Maria. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 116:12(2017), pp. 1520-1525. [10.1038/bjc.2017.103]

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: New evidence from a multicentric study

Lohr, Frank;Magli, Alessandro;
2017

Abstract

Background:The aim of the present study is to evaluate the impact of metastases-directed stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) patients: oligorecurrent PC and oligoprogressive castration-resistant PC (oligo-CRPC).Methods:Inclusion criteria of the present multicentre retrospective analysis were: (1) oligorecurrent PC, defined as the presence of 1-3 lesions (bone or nodes) detected with choline positron emission tomography or CT plus bone scan following biochemical recurrence; (2) oligo-CRPC, defined as metastases (bone or nodes) detected after a prostatic-specific antigen rise during androgen deprivation therapy (ADT). Primary end points were: distant progression-free survival (DPFS) and ADT-free survival in oligorecurrent PC patients; DPFS and second-line systemic treatment-free survival in oligo-CRPC patients.Results:About 100 patients with oligorecurrent PC (139 lesions) and 41 with oligo-CRPC (70 lesions), treated between March 2010 and April 2016, were analysed. After a median follow-up of 20.4 months, in the oligorecurrent group 1-and 2-year DPFS were 64.4 and 43%. The rate of LC was 92.8% at 2 years. At a median follow-up of 23.4 months, in the oligo-CRPC group 1-and 2-year DPFS were 43.2 and 21.6%. Limitations include the retrospective design.Conclusions:Stereotactic body radiotherapy seems to be a useful treatment both for oligorecurrent and oligo-CRPC.
27-apr-2017
116
12
1520
1525
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: New evidence from a multicentric study / Triggiani, Luca; Alongi, Filippo; Buglione, Michela; Detti, Beatrice; Santoni, Riccardo; Bruni, Alessio; Maranzano, Ernesto; Lohr, Frank; D'Angelillo, Rolando; Magli, Alessandro; Bonetta, Alberto; Mazzola, Rosario; Pasinetti, Nadia; Francolini, Giulio; Ingrosso, Gianluca; Trippa, Fabio; Fersino, Sergio; Borghetti, Paolo; Ghirardelli, Paolo; Magrini, Stefano Maria. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 116:12(2017), pp. 1520-1525. [10.1038/bjc.2017.103]
Triggiani, Luca; Alongi, Filippo; Buglione, Michela; Detti, Beatrice; Santoni, Riccardo; Bruni, Alessio; Maranzano, Ernesto; Lohr, Frank; D'Angelillo, Rolando; Magli, Alessandro; Bonetta, Alberto; Mazzola, Rosario; Pasinetti, Nadia; Francolini, Giulio; Ingrosso, Gianluca; Trippa, Fabio; Fersino, Sergio; Borghetti, Paolo; Ghirardelli, Paolo; Magrini, Stefano Maria
File in questo prodotto:
File Dimensione Formato  
VOR_Efficacy of stereotactic body radiotherapy.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 368.38 kB
Formato Adobe PDF
368.38 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1172326
Citazioni
  • ???jsp.display-item.citation.pmc??? 42
  • Scopus 104
  • ???jsp.display-item.citation.isi??? 106
social impact